Jingping Yu

Dr. Jingping Yu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MLMinghe Lv
Minghe Lv
YFYue Feng
Yue Feng
SZSu Zeng
Su Zeng
YZYang Zhang
Yang Zhang
WSWenhao Shen
Wenhao Shen
JYJingping Yu
Jingping Yu
Recent research has demonstrated that the use of artificial intelligence (AI) in radiotherapy (RT) has significantly streamlined the process for physicians to treat patients with tumors; however, bibliometric studies examining the correlation between AI and RT are not available. Providing a thorough overview of the knowledge structure and research hotspots between AI and RT was the main goal of the current study. A search was conducted on the Web of Science Core Collection (WoSCC) database for publications pertaining to AI and RT between 2003 and 2023. VOSviewers, CiteSpace, and the R program “bibliometrix” were used to do the bibliometric analysis. The analysis comprised 615 publications from 64 countries, with USA and China leading the pack. Since 2017, there have been more and more publications about RT and AI every year. The research center that made the biggest contribution to this topic was Maastricht University. The most articles published journal in this field was Frontiers in Oncology, while Medical Physics received the greatest number of citations. Dekker Andre is the author with the greatest number of published articles, while Philippe Lambin was the most often co-cited author. In the newly identified research hotspots, “autocontouring algorithm”, “deep learning”, and “machine learning” stand out as the main terms. In fact, our bibliometric analysis offers insightful information on current research directions and advancements pertaining to the use of AI in RT. For academics looking to understand the connection between AI and RT, this study is a great resource because it highlights current research frontiers and hot trends.

11 September 2020 in Medicine
Verified
Journal Article
Open access
JWJianlin Wang
Jianlin Wang
JLJudong Luo
Judong Luo
ZSZhiqiang Sun
Zhiqiang Sun
FSFei Sun
Fei Sun
ZKZe Kong
Ze Kong
JYJingping Yu
Jingping Yu
DNA methylation is an important epigenetic regulatory mechanism in esophageal carcinoma (EC) and is associated with genomic instability and carcinogenesis. In the present study, we aimed to identify tumor biomarkers for predicting prognosis of EC patients. We downloaded mRNA expression profiles and DNA methylation profiles associated with EC from the Gene Expression Omnibus database. Differentially expressed and differentially methylated genes between tumor tissues and adjacent normal tissue samples were identified. Functional enrichment analyses were performed, followed by the construction of protein–protein interaction networks. Data were validated based on methylation profiles from The Cancer Genome Atlas. Candidate genes were further verified according to survival analysis and Cox regression analysis. We uncovered multiple genes with differential expression or methylation in tumor samples compared with normal samples. After taking the intersection of 3 differential gene sets, we obtained a total of 232 overlapping genes. Functional enrichment analysis revealed that these genes are related to pathways such as “glutathione metabolism,” “p53 signaling pathway,” and “focal adhesion.” Furthermore, 8 hub genes with inversed expression and methylation correlation were identified as candidate genes. The abnormal expression levels of MSN, PELI1, and MTHFD2 were correlated with overall survival times in EC patients ( P < .05). Only MTHFD2 was significantly associated with a pathologic stage according to univariate analysis ( P = .037) and multivariate analysis ( P = .043). Our study identified several novel EC biomarkers with prognostic value by integrated analysis of transcriptomic data and methylation profiles. MTHFD2 could serve as an independent biomarker for predicting prognosis and pathological stages of EC.

22 March 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
FSFei Sun
Fei Sun
YLYingying Lian
Yingying Lian
JWJianlin Wang
Jianlin Wang
LHLijun Hu
Lijun Hu
JLJudong Luo
Judong Luo
JYJingping Yu
Jingping Yu
KIF26B has been identified as an oncogene in several tumors; however, its utility as a prognostic indicator for various cancers has not yet been comprehensively evaluated. Here, we first examined how KIF26B intervenes in thirty-three cancers within the TCGA database, including potential immunological functions, and how it affects the prognosis. Based on the open databases TCGA, TIMER2, GEPIA2, GTEx, CPTAC, and HPA, we found that, when compared with normal tissues, KIF26B is overexpressed in 22 tumor tissues. Following a survival analysis, a relationship between the expression of KIF26B and the prognosis of various cancers was observed. Among the genetic alterations assessed, mutations were the most frequent. On the contrary, high phosphorylation levels of S977 were detected in breast cancer, KIRC, LUAD, and UCEC. We also found positive or negative correlations between KIF26B and the immune infiltration of endothelial cells and cancer-associated fibroblast infiltration. This could imply that patients may benefit from immunotherapy. Finally, KEGG pathways and GO enrichment analyses were implemented to identify the molecular mechanisms of KIF26B. This study illustrates the function of KIF26B from a pan-cancer perspective and offers a new horizon for cancer prognostic and immunotherapeutic investigations.

1 May 2019 in Medicine
Verified
Journal Article
Open access
JYJingping Yu
Jingping Yu
XNXin-Chu Ni
Xin-Chu Ni
ZSZhi-Qiang Sun
Zhi-Qiang Sun
WSWei Sun
Wei Sun
BNBin Nie
Bin Nie
JWJianlin Wang
Jianlin Wang
The aim of this study was to observe pathological response and change in serum vascular endothelial growth factor (VEGF) in esophageal carcinoma (EC) during chemoradiotherapy (CRT). Eighty-nine patients diagnosed with EC were treated with radiotherapy at the Department of Radiotherapy of the Second People's Hospital of Changzhou between May 2008 and December 2014, including 65 patients with CRT. Gastroscopy and pathological examination were conducted 4 weeks afterwards. The pathological responses were classified as complete response (CR) and non-CR. Serum samples were collected from the patients before radiotherapy, during week 4 of radiotherapy, and 1 week after radiotherapy. The VEGF changes were classified as increase, stable, and decrease. The median overall survival (OS) and median progression-free survival (PFS) in the pathological CR group was significantly longer than that of the non-CR group (P < .001). The 1-, 3-, and 5-year OS rates in the non-CR group were lower than that in the CR group (P < .05). Moreover, the 1-, 3-, and 5-year PFS rates in the non-CR group were lower than that in the CR group (P < .05). VEGF serum level was decreased during and after radiotherapy compared with pre-radiotherapy, and the differences were statistically significant (P < .05). The 1-, 3-, and 5-year OS rates in the increased group were lower than that in the decreasing group (P < .05). Moreover, the 1-, 3-, and 5-year PFS rates in the increasing group were lower than that in the decreasing group (P < .05). Pathological response (P < .05), serum VEGF trend (P < .05), and tumor-node-metastasis stage (P < .05) in response to CRT were factors that influenced patient prognosis. Pathological response and serum VEGF change during CRT can predict prognosis of nonsurgical patients with EC. Monitoring these changes is of significance in individualized treatment.

21 May 2024 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
FSFei Sun
Fei Sun
YLYingying Lian
Yingying Lian
MZMengyun Zhou
Mengyun Zhou
JLJudong Luo
Judong Luo
LHLijun Hu
Lijun Hu
JYJingping Yu
Jingping Yu

22 January 2025 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
HZHongwei Zeng
Hongwei Zeng
XEXiangyu E
Xiangyu E
MLMinghe Lv
Minghe Lv
SZSu Zeng
Su Zeng
YFYue Feng
Yue Feng
JYJingping Yu
Jingping Yu
Conventional radiotherapy (CRT) has limited local control and poses a high risk of severe toxicity in large lung tumors. This study aimed to develop an integrated treatment plan that combines CRT with lattice boost radiotherapy (LRT) and monitors its dosimetric characteristics. This study employed cone-beam computed tomography from 115 lung cancer patients to develop a U-Net + + deep learning model for generating synthetic CT (sCT). The clinical feasibility of sCT was thoroughly evaluated in terms of image clarity, Hounsfield Unit (HU) consistency, and computational accuracy. For large lung tumors, accumulated doses to the gross tumor volume (GTV) and organs at risk (OARs) during 20 fractions of CRT were precisely monitored using matrices derived from the deformable registration of sCT and planning CT (pCT). Additionally, for patients with minimal tumor shrinkage during CRT, an sCT-based adaptive LRT boost plan was introduced, with its dosimetric properties, treatment safety in high dose regions, and delivery accuracy quantitatively assessed. The image quality and HU consistency of sCT improved significantly, with dose deviations ranging from 0.15% to 1.25%. These results indicated that sCT is feasible for inter-fraction dose monitoring and adaptive planning. After rigid and hybrid deformable registration of sCT and pCT, the mean distance-to-agreement was 0.80 ± 0.18 mm, and the mean Dice similarity coefficient was 0.97 ± 0.01. Monitoring dose accumulation over 20 CRT fractions showed an increase in high-dose regions of the GTV (P < 0.05) and a reduction in low-dose regions (P < 0.05). Dosimetric parameters of all OARs were significantly higher than those in the original treatment plan (P < 0.01). The sCT based adaptive LRT boost plan, when combined with CRT, significantly reduced the dose to OARs compared to CRT alone (P < 0.05). In LRT plan, high-dose regions for the GTV and D95% exhibited displacements greater than 5 mm from the tumor boundary in 19 randomly scanned sCT sequences under free breathing conditions. Validation of dose delivery using TLD phantom measurements showed that more than half of the dose points in the sCT based LRT plan had deviations below 2%, with a maximum deviation of 5.89%. The sCT generated by the U-Net + + model enhanced the accuracy of monitoring the actual accumulated dose, thereby facilitating the evaluation of therapeutic efficacy and toxicity. Additionally, the sCT-based LRT boost plan, combined with CRT, further minimized the dose delivered to OARs while ensuring safe and precise treatment delivery.